Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: LiPolymer who wrote (6383)	1/27/2000 9:39:00 AM
From: Bill Wexler	Read Replies (1) \| Respond to of 10293

They did it with Zonagen. In the face of incontrovertible evidence that Phentolamine (a 50 year-old generic medication) did not in no way, shape, or form cause erections - even when injected directly into the penis - a CIBC "analyst" issued numerous false reports urging a "strong buy" of Zonagen shares based on ludicrous prospects for Zonagen's fraudulent oral medication for Erectile Dysfunction...a medication whose sole active ingredient was Phentolamine. Even though these reports stressed Zonagen's patents for their pill formulation and 9-figure revenue projections, not once did they mention that even Zonagen's own clinical studies demonstrated the pill was no better than placebo. Based one these reports, I figure small investors got taken to the cleaners to the tune of roughly $300 million. Valence's fraudulent battery technology and unethical management will eventually be its undoing as well.